India Drug Makers Struggle To Follow Lupin Into Japan's Generics Market
This article was originally published in PharmAsia News
Executive Summary
Lupin may have made it, but no other India drug maker has been able to set up business in Japan, the second-largest pharmaceutical market in the world and considered to be worth $90 billion.